“I expect this to continue. I expect this type of performance to continue for the next two years.”

In context

“ndard of care here. Make the investment that's been done. And I think now we're seeing the benefit It fundamentally changed the growth trajectory of our business You know, I'd say five years ago, our CRM business was was flat, flat business, then it moved to a, you know, mid single digit high single digit, and then this quarter hitting double digits. It it's it's it's pretty remarkable also, would say, given the fact that this has historically been a low growth market. So we're obviously taking market share. I give total kudos to the team in terms of how they went about this, all the way from R and D, operations, clinical commercial. I think they've done a really good job. And I think Avera is is just now really hitting its stride. And we're driving uptake in both single and dual chamber. I expect this to continue. I expect this type of performance to continue for the next two years. They've established a very large base of US physicians that are now implanting this. I'd say on the single chamber we're probably about 50% penetrated. And so there's still room to grow there. But half of our implants so far have been dual chamber and and were probably sub 10% penetration over there. And those those penetration rates are are are mostly US. So I think there's a lot of opportunity here for us to do this. And to live up to that vision. We've got great opportunity international too. We're seeing really nice momentum in in in Europe and Japan. And I think the long term aspiration here to be able to convert a significant portion of market. We we estimate the the the low voltage pacing market to be around $4 billion. We wanna convert a significant portion of that and and in doin”